MAPT and Alzheimer disease: Further longitudinal studies are required to determine the threshold needed to distinguish between regular age-related changes in cortical atrophy in AD and other neurodegenerative diseases, and to determine their relationship with cMD signal alongside Aβ and tau pathologies.